FDA warned Allovate that its Allerdent allergenic toothpaste is an unapproved drug and lacks a required biologic license.
What happened
FDA reviewed an online brochure for Allerdent in September 2025 and the website allovate.com, which directs to easily healthcare.com, where Easily Allergy Toothpaste is offered for sale. FDA said the brochure describes allergy immunotherapy by brushing teeth and says the product can be sent directly to a home. FDA found no approved biologics license application (BLA), the approval required for biological products.
What FDA found
The toothpaste is an unapproved new drug because it has no approved drug application.
FD&C Act section 505(a), 21 U.S.C. § 355(a)The toothpaste is an unlicensed biological product because it has no approved biologics license application (BLA).
PHS Act section 351(a)(1), 42 U.S.C. § 262(a)(1)Introducing or delivering the toothpaste into interstate commerce is prohibited.
FD&C Act section 301(d), 21 U.S.C. § 331(d)
What FDA wants
FDA asks Allovate to respond in writing within 15 working days describing steps taken or planned to address the violations and prevent recurrence, with supporting documentation. If it cannot finish in that time, it must explain the delay and completion timeframe; if it disputes the finding, it must include reasoning and supporting information.
Who should pay attention
- allergy immunotherapy companies
- online sellers of drug-claim toothpastes
- regulatory teams checking BLA status
This is a summary. Read the original letter on fda.gov.